340 Spam-Free Article(s) Found
Sort:
Date
Filter:
All
Symbol Name Last Close Mkt Cap DailyStocks'
Rating
Our DailyStocks’ Rating System is a proprietary algorithm that combines the vote of the investor community and legendary trader Richard Dennis’ Turtle Trader System and the System Rules of the Turtle Traders Each day, we generate Buy, Sell, Uptrend or Downtrend signals for 3000 Stocks in the U.S. Markets.
Vote Now!
Tuesday’s Close
AGN Allergan plc. $184.29 $62.56B N/A
Article Searches
Teva (TEVA) Q3 Earnings Beat, 2018 EPS View Up, Shares Rise http://www.zacks.com/stock/news/334690/teva-teva-q3-earnings-beat-2018-eps-view-up-shares-rise?cid=CS-ZC-FT-334690 Nov 02, 2018 - Teva's (TEVA) shares up 15% despite mixed third-quarter results as it increases its earnings and free cash flow guidance for the full year.
Pharma Stock Roundup: PFE, AGN Q3 Earnings, LLY, NVS Collaboration Deals in Focus http://www.zacks.com/stock/news/334564/pharma-stock-roundup-pfe-agn-q3-earnings-lly-nvs-collaboration-deals-in-focus?cid=CS-ZC-FT-334564 Nov 02, 2018 - Pfizer (PFE) and Allergan (AGN) report third-quarter results. Eli Lilly (LLY), Pfizer and Sanofi (SNY) announce collaboration deals.
How the Record-Breaking Sale of a Lichtenstein Painting Changed Agnes Gund's Life https://www.wsj.com/articles/how-the-record-breaking-sale-of-a-lichtenstein-painting-changed-agnes-gunds-life-1540999406?mod=WSJ_GoogleNews Oct 31, 2018 - An art collector and patron turns her talents to criminal justice.
Is a Beat in Store for Editas (EDIT) This Earnings Season? http://www.zacks.com/stock/news/333611/is-a-beat-in-store-for-editas-edit-this-earnings-season?cid=CS-ZC-FT-333611 Oct 31, 2018 - On Editas' (EDIT) third-quarter conference call, investor focus will be on the company's progress with its proprietary genome editing platform based on CRISPR technology.
Allergan PLC (AGN) Q3 2018 Earnings Conference Call Transcript https://www.fool.com/earnings/call-transcripts/2018/10/30/allergan-plc-agn-q3-2018-earnings-conference-call.aspx?source=iedfolrf0000001 Oct 30, 2018 - AGN earnings call for the period ending September 30, 2018.
Allergan Plc (AGN) Q3 2018 Results - Earnings Call Transcript https://seekingalpha.com/article/4215854-allergan-plc-agn-q3-2018-results-earnings-call-transcript?source=feed_sector_healthcare Oct 30, 2018 - Allergan Plc (NYSE:AGN)Q3 2018 Earnings CallOctober 30, 2018 8:30 am ETExecutivesDaphne Karydas - Allergan PlcBrenton L. Saunders - Allergan PlcWilliam J. Meury - Allergan PlcC. David Nicholson - Alle
Allergan (AGN) Tops Q3 Earnings and Revenue Estimates http://www.zacks.com/stock/news/332574/allergan-agn-tops-q3-earnings-and-revenue-estimates?cid=CS-ZC-FT-332574 Oct 30, 2018 - Allergan (AGN) delivered earnings and revenue surprises of 5.99% and 1.87%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?
The Zacks Analyst Blog Highlights: Allergan, Regeneron Pharmaceuticals, Amgen, Alnylam Pharmaceuticals and AMAG Pharmaceuticals http://www.zacks.com/stock/news/332136/the-zacks-analyst-blog-highlights-allergan-regeneron-pharmaceuticals-amgen-alnylam-pharmaceuticals-and-amag-pharmaceuticals?cid=CS-ZC-FT-332136 Oct 29, 2018 - The Zacks Analyst Blog Highlights: Allergan, Regeneron Pharmaceuticals, Amgen, Alnylam Pharmaceuticals and AMAG Pharmaceuticals
Teva (TEVA) to Report Q3 Earnings: What's in the Cards? http://www.zacks.com/stock/news/332222/teva-teva-to-report-q3-earnings-whats-in-the-cards?cid=CS-ZC-FT-332222 Oct 29, 2018 - While pricing erosion in U.S. generics market and lower sales of Copaxone are expected to hurt sales at Teva (TEVA), cost savings from an aggressive restructuring plan will support the bottom line.
5 Drug/Biotech Stocks Likely to Beat Estimates in Q3 Earnings http://www.zacks.com/stock/news/332054/5-drug-biotech-stocks-likely-to-beat-estimates-in-q3-earnings?cid=CS-ZC-FT-332054 Oct 26, 2018 - We take a look at a few stocks that might deliver an earnings beat when they report next week.

Pages: 123456789101112...34

<<<Page 7>